Genentech has inked a licensing and development deal with Bermuda-based biotech Kiniksa Pharmaceuticals for the company’s investigational drug vixarelimab.
VIVJOA is the first and only FDA-approved drug for the treatment of recurrent vulvovaginal candidiasis (RVVC) in females.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.